NCT04729972: A trial that was reported late by Neurotech Pharmaceuticals
This trial has reported, although it was 229 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04729972 |
|---|---|
| Title | Phase II, Multicenter, Open-label Safety Study of Bilateral NT-501 in Participants With Macular Telangiectasia Type 2 |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 21, 2021 |
| Completion date | Dec. 8, 2022 |
| Required reporting date | Dec. 8, 2023, midnight |
| Actual reporting date | July 24, 2024 |
| Date last checked at ClinicalTrials.gov | April 4, 2025 |
| Days late | 229 |